Latozinemab

← Pipeline

Latozinemab

Alector / GSK · Frontotemporal dementia
Mid-stage terminated terminated CT.gov grounded

FTD program targeting the progranulin pathway through sortilin inhibition.

Open Frontotemporal dementia hub Filter main pipeline

Program overview

Mechanism
sortilin inhibition / progranulin elevation
Modality
monoclonal antibody
Phase
Mid-stage
Status
terminated
Recruitment
terminated
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Alector / GSK
Trial IDs
NCT06111014
ClinicalTrials.gov exact matches: NCT06111014

Regions and recruitment

Active in 10 regions
United States Belgium Canada France Germany Italy Netherlands Portugal Sweden United Kingdom

Indication tags

FTD progranulin-linked FTD

Milestones and catalysts

Last milestone
One of the more serious genetically anchored FTD programs worth tracking.
Next expected catalyst
Mid-stage readouts and biomarker alignment.

Related pages

Disease hub Frontotemporal dementia hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Frontotemporal dementia.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Early / Mid-stage active recruiting

Gene-therapy FTD program that helps make the monitor feel like a real neurodegeneration pipeline rather than an Alzheimer's side project.

Shown because it shares same disease bench and shared biology: ftd with Latozinemab.
Mechanism
GRN gene replacement
Modality
AAV gene therapy
Next catalyst
Early safety and biological activity signals in GRN-FTD.
Last verified
20 Apr 2026
Priority 3
Late-stage / Terminated completed completed

A major FTD progranulin program that now functions as an important field-level setback reference rather than an active growth story.

Shown because it shares same disease bench and same modality with Latozinemab.
Mechanism
progranulin elevation
Modality
monoclonal antibody
Next catalyst
No near-term active catalyst, but it matters as context for the FTD field.
Last verified
20 Apr 2026

WVE-004

Wave Life Sciences · Frontotemporal dementia
Priority 3
Early / Mid-stage terminated terminated

A genetically anchored ALS/FTD program whose termination is still important context for anyone taking the pipeline seriously.

Shown because it shares same disease bench and shared biology: ftd with Latozinemab.
Mechanism
C9orf72-targeted oligonucleotide
Modality
oligonucleotide
Next catalyst
No active catalyst, but it remains a useful reference point for C9-directed clinical translation.
Last verified
20 Apr 2026
Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same modality with Latozinemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT06111014 ClinicalTrials.gov search Alector pipeline
Scroll to Top